I am a
Home I AM A Search Login

Papers of the Week


Pain Res Manag


Tolerability of Palmitoylethanolamide in a Pediatric Population Suffering from Migraine: A Pilot Study.


Papetti L, Sforza G, Tullo G, Alaimo Di Loro P, Moavero R, Ursitti F, Ferilli M A N, Tarantino S, Vigevano F, Valeriani M
Pain Res Manag. 2020; 2020:3938640.
PMID: 32377286.


Palmitoylethanolamide (PEA) is emerging as a new therapeutic approach in pain and inflammatory conditions, and it has been evaluated in studies on various painful diseases. The aim of this open-label study was to evaluate the efficacy of ultramicronized PEA (umPEA) in the prophylactic treatment of migraine.